Accurate Mass LC-MS Approaches for Characterization and Quantification of Drugs and Metabolites
A session dedicated to "Accurate Mass LC-MS Approaches for Characterization and Quantification of Drugs and Metabolites" will kick off the fourth day of the technical program on Tuesday at the 57th ASMS Conference in Philadelphia, Pennsylvania.
A session dedicated to “Accurate Mass LC-MS Approaches for Characterization and Quantification of Drugs and Metabolites” will kick off the fourth day of the technical program on Tuesday at the 57th ASMS Conference in Philadelphia, Pennsylvania.
The oral session will begin at 8:30 a.m. with a group from Bristol-Myers Squibb giving a talk on the “Identification of a novel CYP1A2-mediated bioactivation pathway of nimesulide using LTQ-Orbitrap and Q-trap mass spectrometers.”
Li Ma, Qian Ruan, Jinping Gan, W. Griffith Humphreys, and Mingshe Zhu’s presentation will focus on “identification of a novel reactive intermediate derived from oxidative metabolism of nimesulide and the CYP enzyme responsible for the bioactivation.”
Five more presentations will follow the Bristol-Myers Squibb group, with topics ranging from the “Combination of Fast Liquid Chromatography and Quadrupole Time-of-Flight for Quantitative Analysis of Pharmaceuticals in Plasma using Accurate Mass” to “2D mass mapping: novel data visualization method for complex peptide mixtures analysis.”
Wrapping up the morning session will be Olaf Boernsen, Denis Herzog, Stephan Charmont, Nelson Guerreiro, Francois Legay, and Stephan Bek, all from Novartis Pharma AG, Basel, Switzerland. Their talk will be on “Method Development for Absolute Quantitation of Insulin Grows Factor Binding Proteins (IGFBP) in Plasma Samples by Capillary LC-MS.” They will zero in on “Multiplex absolute quantitative MRM assay with increased sensitivity by using sample pretreatment steps and selection of unique peptide transitions.”
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
